2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

cancer cell lysates

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

3

Fluorescent Dyes

1

Peptides

2

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-14985
    BAY 61-3606 dihydrochloride
    Maximum Cited Publications
    10 Publications Verification

    		 Syk Apoptosis Inflammation/Immunology Cancer
    BAY 61-3606 dihydrochloride is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor with a Ki of 7.5 nM an IC50 of 10 nM . BAY 61-3606 dihydrochloride reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell . BAY 61-3606 dihydrochloride induces a large decrease of Syk phosphorylation in K-rn cell lysates . Bay 61-3606 dihydrochloride sensitizes TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells .
    BAY 61-3606 dihydrochloride
  • HY-115501
    (E)-FOBISIN101

    		Ser/Thr Protease Cancer
    (E)-FOBISIN101 is a 14-3-3 protein-protein interaction (14-3-3 protein-protein interaction) inhibitor, with IC50 values of 9.3 and 16.4 μM for disrupting the binding of 14-3-3ζ or 14-3-3γ to PRAS40, respectively. (E)-FOBISIN101 inhibits the binding of 14-3-3 to Raf-1 and proline-rich AKT substrate, and neutralizes the ability of 14-3-3 to activate exotoxin S ADP-ribosyltransferase. (E)-FOBISIN101 is applicable to 14-3-3-mediated cancer research .
    (E)-FOBISIN101
  • HY-176811
    VVD-442

    		Ras PI3K Akt Cancer
    VVD-442 is an inhibitor targeting PI3Kα. VVD-442 covalently binds to Cys242 in the RAS-binding domain of PI3K p110α, induces conformational changes, and disrupts the interaction between PI3K p110α and RAS proteins. VVD-442 also blocks RAS-mediated PI3K activation. VVD-442 can be used in research related to RAS-mutant cancers and HER2-overexpressing cancers .
    VVD-442
  • HY-176812
    VVD-849

    		Ras PI3K Akt Cancer
    VVD-849 is a RAS ligand. VVD-849 covalently binds to Cys242 in the RAS-binding domain of PI3K p110α and promotes RAS/PI3K interaction. VVD-849 partially inhibits pAKT (S473) in HER2-overexpressing tumors. VVD-849 can be used for the research of cancers such as breast cancer .
    VVD-849
  • HY-100335
    PCI-33380
    1 Publications Verification

    		 Fluorescent Dye Btk Cancer
    PCI-33380 is a fluorescent probe ( (Ex=532 nm, Em=555 nm). PCI-33380 consists of a (BTK) inhibitor PCI-32765 (HY-10997) attaching with a Bodipy-FL fluorophore via a piperazine linker. PCI-33380 binds predominantly to Btk in B cell lysates with cell permeable activity. PCI-33380 can be used for imaging live cancer cells such as non-Hodgkin lymphoma research
    PCI-33380
  • HY-12291
    HG6-64-1

    HMSL 10017-101-1

    		 Raf Apoptosis Cancer
    HG6-64-1 (HMSL 10017-101-1) is a B-raf kinase modulator.HG6-64-1 modulates B-raf kinase activity, including the V600E mutant form and the drug-resistant gatekeeper mutation T529I. HG6-64-1 is a germinal center kinase inhibitor. HG6-64-1 induces cell cycle arrest and apoptosis. HG6-64-1 can be used for the research of diffuse large B-cell lymphoma (DLBCL) .
    HG6-64-1
  • HY-159805
    CDK2-IN-31

    		CDK Cancer
    CDK2-IN-31 is a CCNE1:CDK2 complex inhibitor with an IC50 of 0.13 μM. CDK2-IN-31 binds to a cryptic allosteric pocket at the CCNE1:CDK2 interface, inducing structural rearrangements of the CDK2 A-loop that disrupt the kinase's active conformation and interfere with substrate binding. CDK2-IN-31 inhibits phosphorylation of retinoblastoma protein 1 (RB1) in CCNE1-dependent ovarian cancer cells. CDK2-IN-31 impairs coenrichment of protein PRC1 with CCNE1-N112C:CDK2 complexes. CDK2-IN-31 can be used for the research of ovarian cancer .
    CDK2-IN-31
  • HY-76474A
    BAY 61-3606 hydrochloride
    4 Publications Verification

    		 Apoptosis Syk Inflammation/Immunology Cancer
    BAY 61-3606 hydrochloride is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor with a Ki of 7.5 nM and an IC50 of 10 nM . BAY 61-3606 hydrochloride reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell. BAY 61-3606 hydrochloride induces a large decrease of Syk phosphorylation in K-rn cell lysates. BAY 61-3606 hydrochloride sensitizes TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells.
    BAY 61-3606 hydrochloride
  • HY-76474
    BAY 61-3606

    		Syk Apoptosis Inflammation/Immunology Cancer
    BAY 61-3606 is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor with a Ki of 7.5 nM and an IC50 of 10 nM . BAY 61-3606 reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell . BAY 61-3606 induces a large decrease of Syk phosphorylation in K-rn cell lysates . Bay 61-3606 sensitizes TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells .
    BAY 61-3606
  • HY-145749
    PARPYnD

    		PARP Cancer
    PARPYnD is a PARP enzyme photoaffinity probe (AfBP) based on the triple PARP1/2/6 inhibitor AZ9482 (HY-119653), which induces breast cancer Formation of multipolar spindles (MPS) in cells. PARPYnD inhibits PAPR wih IC50 of 38 nM (PARP1), 6 nM (PARP2), 230 nM (PARP6), respectively. PARPYnD enriches recombinant PARP6 incorporated into cell lysates and inhibits PARP6 in cell-free assays, but it does not label PARP6 in intact cells .
    PARPYnD
  • HY-125209A
    TH5427 hydrochloride

    		Apoptosis PARP DNA/RNA Synthesis Cancer
    TH5427 hydrochloride is a NUDT5 inhibitor with a human target IC50 of 29 nM, ~690-fold selectivity over MTH1 in vitro, and selective functional inhibition over other NUDIX hydrolases including NUDT9 .TH5427 hydrochloride binds to the active site of NUDT5, blocking enzymatic activity related to ADP-ribose metabolism and PAR-derived ATP synthesis .TH5427 hydrochloride blocks progestin-dependent nuclear ATP synthesis, impairs progestin-induced chromatin remodeling, inhibits histone H1 displacement, disrupts progestin-dependent gene regulation, and abrogates progestin-dependent proliferation in breast cancer cells .TH5427 hydrochloride functions as a versatile probe to study nuclear ATP dynamics and ADP-ribose-related metabolism in cells .TH5427 hydrochloride engages NUDT5 at physiological temperatures, as demonstrated by Drug Affinity Responsive Target Stability (DARTS) assay .TH5427 hydrochloride stabilizes NUDT5 against thermal denaturation in cell lysates and intact cells, as shown by cellular thermal shift assay (CETSA) .TH5427 hydrochloride functionally inhibits NUDT5 activity, leading to downstream effects on oxidative DNA damage and DNA replication in triple-negative breast cancer (TNBC) cells .TH5427 hydrochloride suppresses proliferation of TNBC cells without inducing cell death or apoptosis, slows DNA replication in TNBC cells, promotes accumulation of oxidative DNA lesions, and triggers DNA damage response in TNBC cells .TH5427 hydrochloride suppresses growth of TNBC cells in vitro, inhibits growth of TNBC xenograft tumors in nude mice in vivo, and shows greater potency against TNBC cell lines compared to ER-positive and normal-like breast cell lines .TH5427 hydrochloride can be used for the research of breast cancer and triple-negative breast cancer .
    TH5427 hydrochloride
  • HY-D3393
    JQ1-FITC TFA

    		Fluorescent Dye Epigenetic Reader Domain Cancer
    JQ1-FITC TFA is a BRD4-binding fluorescent tracer. JQ1-FITC TFA binds to BRD4 BD1, BD2, recombinant bromodomains, and endogenous BRD4 in cell lysates. JQ1-FITC TFA can be used for the research of breast cancer and cancer (Ex/Em = 495/525 nm) .
    JQ1-FITC TFA
  • HY-186111
    BAY-297

    		PI5P4K Cancer
    BAY-297 is a PIP4K2A inhibitor. BAY-297 binds to PIP4K2A in intact cells and cell lysates. BAY-297 serves as a chemical probe for investigating the PIP4K2A signaling pathway and its roles in physiological conditions such as cancer .
    BAY-297
  • HY-185205
    VVD-484

    		PI3K Akt Cancer
    VVD-484 is a PI3K p110α inhibitor with an IC50 of 0.59 μM against human targets.,VVD-484, classified as a "silent ligand", forms a covalent bond with Cys242 of PI3K p110α without disrupting the p110α-KRAS G12C interaction. VVD-484 inhibits phosphorylation (S473) of AKT via a RAS-independent pathway. VVD-484 can be used in the research of HER2-overexpressing cancers .
    VVD-484
  • HY-100335R
    PCI-33380 (Standard)

    		Fluorescent Dye Reference Standards Btk Cancer
    PCI-33380 (Standard) is the analytical standard of PCI-33380 (HY-100335). This product is intended for research and analytical applications. PCI-33380 is a fluorescent probe ( (Ex=532 nm, Em=555 nm). PCI-33380 consists of a (BTK) inhibitor PCI-32765 (HY-10997) attaching with a Bodipy-FL fluorophore via a piperazine linker. PCI-33380 binds predominantly to Btk in B cell lysates with cell permeable activity. PCI-33380 can be used for imaging live cancer cells such as non-Hodgkin lymphoma research
    PCI-33380 (Standard)
  • HY-182755
    Steroid sulfatase-IN-12

    		Steroid Sulfatase Cancer
    Steroid sulfatase-IN-12 is a steroid sulfatase inhibitor. Steroid sulfatase-IN-12 inhibits the activity of steroid sulfatase. Steroid sulfatase-IN-12 can be used in research related to hormone receptor-positive/HER2-negative breast cancer .
    Steroid sulfatase-IN-12
  • HY-D3189
    5GluAF-2MeTG

    		Fluorescent Dye PSMA Cancer
    5GluAF-2MeTG is an activatable fluorescent probe targeting the glutamate carboxypeptidase (CP) activity of PSMA (Ex/Em=490/500-600 nm). After being hydrolyzed by PSMA, 5GluAF-2MeTG releases a cell membrane-permeable fluorescent product, and achieves fluorescence activation by disrupting donor-excited photoinduced electron transfer (d-PeT). 5GluAF-2MeTG enables fluorescence imaging of live PSMA-expressing prostate cancer cells in vitro and visualizes the carboxypeptidase activity of PSMA. 5GluAF-2MeTG can be used to detect prostate cancer regions in preclinical excised tissue specimens .
    5GluAF-2MeTG
  • HY-P11621
    JWP24

    		E1/E2/E3 Enzyme Cancer
    JWP24 is the first cell membrane-permeable peptide inhibitor of MAGE-A4, with an IC50 of 200 nM against human MAGE-A4. JWP24 binds to intracellular targets while retaining binding activity, disrupts the interaction between MAGE-A4 and RAD18, and does not induce cytotoxicity at effective concentrations. JWP24 is applicable for cancer-related research .
    JWP24
  • HY-182253
    WS-691

    		P-glycoprotein Cancer
    WS-691 is an orally active, selective ABCB1 modulator. WS-691 selectively stabilizes ABCB1 via direct binding to ABCB1. WS-691 inhibits the efflux function of ABCB1 and activates ABCB1 ATPase activity. WS-691 elevates intracellular Paclitaxel (HY-B0015) levels and reduces the required dose of Paclitaxel in cancer cells overexpressing ABCB1. WS-691 increases the sensitivity of colon cancer cells to Paclitaxel .
    WS-691
  • HY-D3353
    PSMA-SulfoCy7

    		PSMA Cancer
    PSMA-SulfoCy7 is a high-affinity imaging agent targeting PSMA/GCPII (with a Ki of 18.1 nM for human PSMA). PSMA-SulfoCy7 regulates PSMA-dependent NAAG hydrolysis. PSMA-SulfoCy7 exhibits excellent in vivo imaging capability, enabling clear visualization of PSMA-expressing tumors in xenograft models, with no obvious toxicity even at a dose of 87.9 mg/kg. PSMA-SulfoCy7 is widely used in prostate cancer-related studies .
    PSMA-SulfoCy7
  • HY-185414
    KB05-Biotin

    		Biochemical Assay Reagents Others
    KB05-Biotin is streptavidin-conjugated KB05 (HY-149461) that retains the site-specific cysteine covalent reactivity of KB05, enabling specific detection of target proteins via the biotin-streptavidin system. KB05-Biotin serves as a site-specific probe in ELISA-ABPP assays for screening electrophilic small molecules that bind to scout fragment-sensitive cysteines on target proteins in cell lysates, without the need for protein purification .
    KB05-Biotin
  • HY-183603
    FRC-222

    		DNA/RNA Synthesis Cancer
    FRC-222 is a CHD1 tandem chromodomain inhibitor with a Kd of 0.15 μM and an IC50 of 0.18 μM. FRC-222 binds to the H3K4me3 binding site of CHD1 tandem chromodomain via aromatic cage interactions and extended ligand contacts. FRC-222 can be used for the research of prostate cancer[1].
    FRC-222
  • HY-182673
    VT102

    		YAP Cancer
    VT102 is a TEAD1 inhibitor with a human IC50 of 391 nM. VT102 inhibits auto-palmitoylation, attenuates YAP/TEAD1 interaction, reduces expression of TEAD target genes, and inhibits YAP-mediated luciferase reporter activity. VT102 exerts weak cell growth inhibitory activity in cancer cells. VT102 can be used for the research of cancer .
    VT102
  • HY-182681
    AV-9606-129

    		Deubiquitinase c-Myc Cancer
    AV-9606-129 is a USP28 inhibitor with an IC50 of < 1 μM. AV-9606-129 inhibits the enzymatic activity of USP28 and downregulates the protein levels of c-Myc and c-Myb. AV-9606-129 can be used in cancer research .
    AV-9606-129
  • HY-121511
    EML631

    		Epigenetic Reader Domain Wnt Cancer
    EML631 is a SPIN1 inhibitor with a Kd of 3-7 μM. EML631 interacts with the second Tudor domain of SPIN1 and blocks its ability to read the H3K4me3 histone mark. EML631 inhibits the coactivator activity of SPIN1 in the Wnt signaling pathway and reduces the activity of Wnt response reporter genes. EML631 can be used in cancer-related research .
    EML631
  • HY-183740
    NAIA

    N-Acryloylindole-alkyne

    		 Biochemical Assay Reagents Others
    NAIA (N-Acryloylindole-alkyne) is a cysteine-reactive probe. NAIA can be used as an imaging agent, proteome profiling agent, and covalent ligand screening tool .
    NAIA
  • HY-182896
    HKC54

    		TRP Channel Calcium Channel Neurological Disease Cancer
    HKC54 is a selective TRPV2 antagonist with an IC50 of 0.4 μM. HKC54 binds directly to TRPV2 and inhibits TRPV2-mediated calcium influx. HKC54 inhibits glioblastoma cell migration in vitro and breast cancer metastasis in vivo. HKC54 can be used for the research of breast cancer lung metastasis .
    HKC54
  • HY-183568
    MAT2A-IN-26

    		Methionine Adenosyltransferase (MAT) Cancer
    MAT2A-IN-26 is an orally active MAT2A inhibitor with a human IC50 of 17.53 nM. MAT2A-IN-26 inhibits the enzymatic activity of MAT2A, thereby reducing the levels of S-adenosylmethionine (SAM) and symmetric dimethylarginine (sDMA). MAT2A-IN-26 inhibits the proliferation of MTAP-deficient cancer cells and induces anti-tumor efficacy in xenograft models. MAT2A-IN-26 can be used in non-small cell lung cancer research .
    MAT2A-IN-26
  • HY-123599
    IACS-4619

    		DNA/RNA Synthesis Cancer
    IACS-4619 (compound 4) is a highly selective 2-aminopyrimidine-based MTH1 (MutT homolog 1) inhibitor (IC50=0.2 nM). IACS-4619 inhibits MTH1 by blocking its hydrolysis of oxidized purine nucleotides such as 8-oxo-dGTP, thereby preventing MTH1 from inhibiting the incorporation of oxidized nucleotides into DNA. IACS-4619 significantly inhibits endogenous MTH1 activity in MTH1-overexpressing U2OS cells, but without antiproliferative or cytotoxic effects on various human cancer and normal cell lines. IACS-4619 can be used in oncology research related to the MTH1 target .
    IACS-4619
  • HY-183741
    VVD-844

    		PI3K Akt Cancer
    VVD-844 is an orally active covalent inhibitor of PI3Kα, which inhibits Pl3Kα/p110α interaction with an IC50 of 4 nM. VVD-844 covalently binds to Cys 242 in the RAS binding domain of p110α, blocking RAS-p110α interaction and inhibiting PI3Kα activity. VVD-844 inhibits PI3Kα signaling activation in HER2-overexpressing cells via a RAS-independent mechanism. VVD-844 suppresses tumor growth in mouse. VVD-844 can be used for the research of cancers .
    VVD-844

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: